REFERENCES
V. P. Shah, K. K. Midah, S. Dighe, I. J. McGilveray, J. P. Skelley, A. Yacobi, T. Layloff, C. T. Viswanathan, C. E. Cook, R. D. McDowall, K. A. Pittman, and S. Spector. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Pharm. Res. 9:588–592 (1992).
V. P. Shah, K. K. Midha, J. W. A. Findlay, H. M. Hill, J. D. Hulse, J. McGilveray, G. McKay, K. J. Miller, R. N. Patnaik, M. L. Powell, A. Tonelli, C. T. Viswanathan, and A. Yacobi. Bioanalytical methods validation—a revisit with a decade of progress. Pharm. Res. 17:1551–1557 (2000).
J. W. Findlay, W. C. Smith, J. W. Lee, G. D. Nordblom, I. Das, B. S. DeSilva, M. N. Khan, and R. R. Bowsher. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 21:1249–1273 (2000).
H. T. Karnes, G. Shiu, and V. P. Shah. Validation of bioanalytical methods. Pharm. Res. 8:421–426 (1991).
J. Neter, W. Wasserman, and M. H. Kutner. Aptness of model and remedial measures. In Applied Linear Regression Models. Richard D. Irwin, Inc., Homewood, Illinois, 1983. pp. 109–146.
M. A. Takacs, S. J. Jacobs, R. M. Bordens, and S. J. Swanson. Detection and characterization of antibodies to PEG-IFN-alpha2b using surface plasmon resonance. J. Interferon Cytokine Res. 19:781–789 (1999).
[FDA] Food and Drug Administration. Center for Biologics Evaluation and Research, Meeting of the Biological Response Modifiers Advisory Committee. Thursday, July 15, 1999.
G. J. Downing. Biomarkers and surrogate endpoints: clinical research and applications. Elsevier Science, Amsterdam, The Netherlands 2000.
M. Wadhwa and R. Thorpe. Standardization and calibration of cytokine immunoassays: meeting report and recommendations. Cytokine 9:791–793 (1997).
A. Ledur, C. Fitting, B. David, C. Hamberger, and J. M. Cavaillon. Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards. J. Immunol. Methods 186:171–179 (1995).
R. O. Kringle. An assessment of the 4-6-20 rule for acceptance of analytical runs in bioavailability, bioequivalence, and pharmacokinetic studies. Pharm. Res. 11:556–560 (1994).
C. Hartmann, D. L. Massart, and R. D. McDowall. An analysis of the Washington Conference Report on bioanalytical method validation. J. Pharm. Biomed. Anal. 12:1337–13343 (1994).
R. O. Kringle and R. C. Khan-Malek. A statistical assessment of the recommendations from a conference on analytical methods validation in bioavailability, bioequivalence, and pharmacokinetic studies. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, August 13–18, 1994. 510–514.
P. Hubert, P. Chiap, J. Crommen, B. Boulanger, E. Chapuzet, N. Mercier, S. Bervoas-Martin, P. Chevalier, D. Grandjean, P. Lagorce, M. Lallier, M. C. Laparra, M. Laurentie, and J. C. Nivet. The SFSTP guide on the validation of chromatographic methods for drug analysis: from the Washington Conference to the laboratory. Anal. Chim. Acta 391:135–148 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miller, K.J., Bowsher, R.R., Celniker, A. et al. Workshop on Bioanalytical Methods Validation for Macromolecules: Summary Report. Pharm Res 18, 1373–1383 (2001). https://doi.org/10.1023/A:1013062600566
Issue Date:
DOI: https://doi.org/10.1023/A:1013062600566